p53 as a prognostic marker associated with the risk of mortality for oral squamous cell carcinoma

Cutilli,Tommaso; Leocata,Pietro; Dolo,Vincenza; Altobelli,Emma

doi:10.3892/ol.2016.4742

p53 as a prognostic marker associated with the risk of mortality for oral squamous cell carcinoma

Authors:
- Tommaso Cutilli
- Pietro Leocata
- Vincenza Dolo
- Emma Altobelli
View Affiliations

Affiliations: Department of Life, Health and Environmental Sciences, Maxillofacial Surgery Unit, University of L'Aquila, I‑67100 L'Aquila, Italy, Department of Life, Health and Environmental Sciences, Pathological Anatomy Unit, University of L'Aquila, I‑67100 L'Aquila, Italy, Department of Life, Health and Environmental Sciences, Clinical Pathology Unit, University of L'Aquila, I‑67100 L'Aquila, Italy, Department of Life, Health and Environmental Sciences, Medical Statistics and Epidemiology Unit, University of L'Aquila, I‑67100 L'Aquila, Italy
Published online on: June 16, 2016 https://doi.org/10.3892/ol.2016.4742
Pages: 1046-1050

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oral squamous cell carcinoma (OSCC) is often associated with a poor prognosis. The purpose of the present study was to investigate survival and the risk of mortality in OSCC with regard to stage, tumor site and p53 expression. A retrospective study was performed on 150 non‑consecutive cases of OSCC that were observed between January 1992 and January 2012, and were selected from a total of 580 patients according to the criteria of the homogeneity of histopathological grading (G2). The medical records were reviewed for 48 cases with disease at stage I [37 males, age 64.7±5.7 years (mean age±standard deviation); 11 females, age 70.0±3.37 years]; 27 cases with stage II (15 males, age 64.5±5.6 years; 12 females, age 69.2±3.9 years); 58 cases with stage IVa (42 males, age 66.9±5.3 years; 16 females, age 64.2±6.5 years); and 17 cases with stage IVb (16 males, age 65.7±5.4 years; 1 female, age 69 years). Monoclonal p53 antibody (clone DO‑7) was used to perform the p53 immunohistochemical study. A significant association was found between the site of the tumor and p53 overexpression (P<0.0001). Stage I‑II cases showed a higher cumulative probability of a 24‑month survival time than stage IVa‑IVb cases (P<0.0001). Cheek, floor and soft palate tumors showed a worse prognosis (P<0.0001) and tumors with p53 overexpression >50% showed a poor survival rate (P<0.0001) compared with tumors of the attached gingiva, tongue and retromolar trigone. The findings allowed the quantification of the risk mortality from OSSC with regard to stage, tumor site and the p53 expression pattern of the tumor. Data supported the absolute indications for wide surgical margins (radical surgery) in cases of T1‑T2 N0 tumors of the tongue, floor, retromolar trigone and attached gingiva when p53 overexpression is >50% in association with a higher risk of mortality compared with when p53 overexpression is <50%.

View Figures

View References

1	Durmus K, Apuhan T and Ozer E: Transoral robotic surgery for retromolar trigone tumours. Acta Otorhinolaryngol Ital. 33:425–427. 2013.PubMed/NCBI
2	Freudlsperger C, Bodem JP, Engel E and Hoffmann J: Mandibular reconstruction with a prefabricated free vascularized fibula and implant-supported prosthesis based on fully three-dimensional virtual planning. J Craniofac Surg. 25:980–982. 2014. View Article : Google Scholar : PubMed/NCBI
3	Bànkfalvi A and Piffkò J: Prognostic and predictive factors in oral cancer: The role of the invasive tumor front. J Oral Pahol Med. 29:291–298. 2000. View Article : Google Scholar
4	Jan JC, Hsu WH, Liu SA, Wong YK, Poon CK, Jiang RS, Jan JS and Chen IF: Prognostic factors in patients with buccal squamous cell carcinoma: 10-year experience. J Oral Maxillofac Surg. 69:396–404. 2011. View Article : Google Scholar : PubMed/NCBI
5	Liao CT, Huang SF, Chen IH, Kang CJ, Lin CY, Fan KH, Wang HM, Ng SH, Hsueh C, Lee LY, et al: Outcome analysis of patients with pN2 oral cavity cancer. Ann Surg Oncol. 17:1118–1126. 2010. View Article : Google Scholar : PubMed/NCBI
6	Holmes JD, Martin RA and Gutta R: Characteristics of head and neck cancer patients referred to an oral and maxillofacial surgeon in the United States for management. J Oral Maxillofac Surg. 68:555–561. 2010. View Article : Google Scholar : PubMed/NCBI
7	Pérez-Sayáns M, Somoza-Martín JM, Barros-Angueira F, Reboiras-López MD, Gándara Rey JM and García-García A: Genetic and molecular alterations associated with oral squamous cell cancer (Review). Oncol Rep. 22:1277–1282. 2009. View Article : Google Scholar : PubMed/NCBI
8	Schwartz JL: Biomarkers and molecular epidemiology and chemoprevention of oral carcinogenesis. Crit Rev Oral Biol Med. 11:92–122. 2000. View Article : Google Scholar : PubMed/NCBI
9	Shah NG, Trivedi TI, Tankshali RA, Goswami JA, Shah JS, Jetly DH, Kobawala TP, Patel KC, Shukla SN, Shah PM and Verma RJ: Molecular alterations in oral carcinogenesis: Significant risk predictors in malignant transformation and tumor progression. Int J Biol Markers. 22:132–143. 2007.PubMed/NCBI
10	Shah NG, Trivedi TI, Tankshali RA, Goswami JV, Jetly DH, Shukla SN, Shah PM and Verma RJ: Prognostic significance of molecular markers in oral squamous cell carcinoma: A multivariate analysis. Head Neck. 31:1544–1556. 2009. View Article : Google Scholar : PubMed/NCBI
11	Shillitoe EJ, May M, Tale V, Lethanakul C, Enseley JF, Strausberg RL and Gutkind JS: Genome-wide analysis of oral cancer-early results from the cancer genome anaromy project. Oral Oncol. 36:8–16. 2000. View Article : Google Scholar : PubMed/NCBI
12	Murugan AK, Munirajan AK and Tsuchida N: Ras oncogenes in oral cancer: The past 20 years. Oral Oncol. 48:383–392. 2012. View Article : Google Scholar : PubMed/NCBI
13	Saito T, Nakajima T and Mogi K: Immunohistochemical analysis of cell cycle-associated proteins p16, pRb, p53, p27 and Ki-67 in oral cancer and precancer with special reference to verrucous carcinoma. J Oral Pathol Med. 28:226–232. 1999. View Article : Google Scholar : PubMed/NCBI
14	Sidransky D, Boyle J and Koch W: Molecular screening. Prospects for a new approach. Arch Otolaryngol Head Neck Surg. 119:1187–1190. 1993. View Article : Google Scholar : PubMed/NCBI
15	Boyle JO, Hakim J, Koch W, van der Riet P, Hruban RH, Roa RA, Correo R, Eby YJ, Ruppert JM and Sidransky D: The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res. 53:4477–4480. 1993.PubMed/NCBI
16	Jones A: A general review of the p53 gene and oral squamous cell carcinoma. Ann R Australas Coll Dent Surg. 14:66–69. 1998.PubMed/NCBI
17	Nylander K, Dabelsteen E and Hall PA: The p53 role molecule and its prognostic role in squamous cell carcimonas of the head and neck. J Oral Pathol Med. 29:413–425. 2000. View Article : Google Scholar : PubMed/NCBI
18	Tandon S, Tudur-Smith C, Riley RD, Boyd MT and Jones TM: A systematic review of p53 as a prognostic factor of survival in squamous cell carcinoma of the four main anatomical subsites of the head and neck. Cancer Epidemiol Biomarkers Prev. 19:574–587. 2010. View Article : Google Scholar : PubMed/NCBI
19	Cutilli T, Papola F and Corbacelli A: p53 overexpression and mutation, chemoresistance and patient survival in oral and maxillofacial squamous carcinoma. J Chemother. 9:123–124. 1997. View Article : Google Scholar : PubMed/NCBI
20	Cutilli T, Papola F, Di Emidio P and Corbacelli A: p53 tumor suppressor protein and H-RAS oncogene in maxillofacial tumors: Immunohistochemical and genetic investigaion, induction chemotherapy response and prognosis evaluation. J Chemother. 10:411–417. 1998. View Article : Google Scholar : PubMed/NCBI
21	Cutilli T, Leocata P, Dolo V and Altobelli E: Evaluation of p53 protein as a prognostic factor for oral cancer surgery. Br J Oral Maxillofac Surg. 51:922–927. 2013. View Article : Google Scholar : PubMed/NCBI
22	Green FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG and Morrow M: AJCC cancer staging manual. 6th. Springer; New York: 2002, View Article : Google Scholar
23	World Health Organization = IARC monographs on the evaluation of carcinogenic risks to humans: Biological Agents. 100B. A review of human carcinogens. International Agency for Research on Cancer; Lyon: 2012
24	Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG and Morrow M: AJCC Cancer Staging Manual. 6th. Springer-Verlag; New York, NY: 2002, View Article : Google Scholar
25	Specenier P and Vermorken JB: Advances in the systemic treatment of head and neck cancers. Curr Opin Oncol. 22:200–205. 2010. View Article : Google Scholar : PubMed/NCBI
26	Jenwitheesuk K, Surakunprapha P, Chowchuen B, Tangvoraphongchai V, Pesee M, Krusun S and Supaadirek C: Results of multidisciplinary therapy of squamous cell carcinoma of the buccal mucosa at Srinagarind Hospital, Thailand. J Med Assoc Thai. 93:1262–1267. 2010.PubMed/NCBI
27	Hakeem AH, Pradhan SA, Tubachi J and Kannan R: Outcome of per oral wide excision of T1-2 N0 localized squamous cell cancer of the buccal mucosa-analysis of 156 cases. Laryngoscope. 123:177–180. 2013. View Article : Google Scholar : PubMed/NCBI